PRIMARY NON-HODGKINS-LYMPHOMAS OF THE PARANASAL SINUSES AND NASAL CAVITY - A REPORT OF 18 CASES WITH STAGE IE DISEASE

被引:25
作者
TRAN, LM
MARK, R
FU, YS
CALCATERRA, T
JUILLARD, G
机构
[1] UNIV CALIF LOS ANGELES,DEPT RADIAT ONCOL,LOS ANGELES,CA 90024
[2] UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90024
[3] UNIV CALIF LOS ANGELES,DIV HEAD & NECK SURG,LOS ANGELES,CA 90024
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1992年 / 15卷 / 03期
关键词
NON-HODGKINS LYMPHOMA; STAGE IE DISEASE; MAXILLARY SINUS;
D O I
10.1097/00000421-199206000-00008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
During a 26-year period (1961-1987), a total of 18 patients with primary non-Hodgkin's lymphoma (NHL) of the paranasal sinuses and nasal cavity received radiation therapy at (University of California at Los Angeles) UCLA Medical Center. At the time of diagnosis and using the available diagnostic methods, none of these patients had clinically detectable disease beyond the paranasal sinuses. All 18 patients were staged IE by the Ann-Arbor system. When the patients were staged according to the AJC staging system for epithelial tumors, half presented with advanced T3-4 disease. Diffuse histiocytic lymphoma was the most common histology (eight cases) and maxillary sinus, the most common site of origin (11 cases). All nine T1-2 tumors received radiation therapy alone, while radiation and chemotherapy was used in seven of nine advanced T3-4 staged tumors. The mean follow-up was 71 months. At last follow-up, eight of nine T1-2 patients were rendered disease-free. In contrast, only four of nine T3-4 patients had long-term disease-free survival. Seventy-five percent of the failure occurred within 2 years. Radiation therapy alone achieves high local control in small tumors (T1-2), while large tumors (T3-4) require aggressive combined treatment, i.e., radiation and chemotherapy.
引用
收藏
页码:222 / 225
页数:4
相关论文
共 25 条
[1]   CHEMOTHERAPY AS DEFINITIVE TREATMENT OF STAGE-I-II LARGE CELL AND DIFFUSE MIXED LYMPHOMAS [J].
CABANILLAS, F .
HEMATOLOGICAL ONCOLOGY, 1985, 3 (01) :25-31
[2]   COMBINED RADIOTHERAPY-CHEMOTHERAPY FOR EARLY STAGES NON-HODGKINS LYMPHOMA - THE 1975-1980 EORTC CONTROLLED LYMPHOMA TRIAL [J].
CARDE, P ;
BURGERS, JMV ;
VANGLABBEKE, M ;
HAYAT, M ;
COSSET, JM ;
SOMERS, R ;
SIZOO, W ;
QASIM, MM ;
LEFUR, R ;
ABBATUCCI, JS ;
TUBIANA, M .
RADIOTHERAPY AND ONCOLOGY, 1984, 2 (04) :301-312
[3]  
FRIERSON HF, 1979, CANCER, V43, P611
[4]  
FU YS, 1979, CANCER, V43, P611, DOI 10.1002/1097-0142(197902)43:2<611::AID-CNCR2820430231>3.0.CO
[5]  
2-X
[6]   PROGNOSTIC FACTORS IN NODULAR LYMPHOMAS - A MULTIVARIATE-ANALYSIS BASED ON THE PRINCESS-MARGARET-HOSPITAL EXPERIENCE [J].
GOSPODAROWICZ, MK ;
BUSH, RS ;
BROWN, TC ;
CHUA, T .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (04) :489-497
[7]  
HOPPE RT, 1987, CURRENT PROBLEMS NOV, P11
[8]  
JACOBS C, 1986, ARCH OTOLARYNGOL, V112, P654
[9]   NON-HODGKINS LYMPHOMAS OF HEAD AND NECK EXTRANODAL SITES [J].
JACOBS, C ;
HOPPE, RT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1985, 11 (02) :357-364
[10]  
LONG G, 1990, P AM SOC CLIN ONCOL, V9, P264